-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: David Thomas, CFA
David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.
Latest Posts
Does Biotech History Repeat?
According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history. When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. Read More >
Update: Indices, IPOs, and New Drug Approvals
Here is a look at year to date (YTD) numbers through the end of February for the biotech indices, initial public offerings, and recent FDA Approvals. 1. Indices: The Nasdaq Biotech Index held the January jump through February, settling at + 14% YTD. The concentrated BTK slipped in February, but has outpaced the NBI since January 1st. YTD, both biotech indices have significantly outperformed the broader market. In contrast, the NYSE Pharmaceuticals Index has not Read More >
Oncology Clinical Trials – Secrets of Success
At last year’s BIO CEO & Investor Conference, BIO and BioMedTracker presented data showing that drugs in development for oncology indications had the lowest overall clinical trial success rate of all therapeutic areas in development since 2004. We have updated these numbers to include clinical trials through December 2011. Although overall success rates did improve slightly, oncology remained in last place. The chart below illustrates why oncology’s overall success rate is so low relative to Read More >
BIO CEO 2012 Opening Remarks
The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >
A Very Big BTK January
We all heard reports that January was a great start to 2012 for the stock market, and even more so for Biotech. But how big was it, really? The Amex Biotech Index (the “BTK“) had its biggest January on record, since 1992, with a +21% pop: The companies behind the numbers? The Nasdaq Biotech Index was up 11%, the best in a decade. The January 2000 jump of 15% is still a tough month to beat Read More >
